[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Sta-tistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Shi, Y., Au, J.S., Thongpra-sert, S., Srinivasan, S., Tsai, C.M., Khoa, M.T., Heeroma, K., Itoh, Y., Cornelio, G. and Yang, P.C. (2014) A Prospec-tive, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). Journal of Thoracic Oncology, 9, 154-162.
https://doi.org/10.1097/JTO.0000000000000033
|
[3]
|
Nan, X., Xie, C., Yu, X. and Liu, J. (2017) EGFR TKI as First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer. Oncotarget, 8, 75712-75726. https://doi.org/10.18632/oncotarget.20095
|
[4]
|
Santaniello, A., Napolitano, F., Servetto, A., et al. (2019) Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. Cancers (Basel), 11, 1419. https://doi.org/10.3390/cancers11101419
|
[5]
|
刘丽萍, 刘苓霜. 程序性死亡蛋白1/程序性死亡蛋白配体1抑制剂在表皮生长因子受体突变晚期肺癌中的应用进展[J]. 中华肿瘤防治杂志, 2023, 30(1): 54-60.
|
[6]
|
Jiang, L., Guo, F., Liu, X., et al. (2019) Continuous Targeted Kinase Inhibitors Treatment Induces Upregu-lation of PD-L1 in Resistant NSCLC. Scientific Reports, 9, Article No. 3705. https://doi.org/10.1038/s41598-018-38068-3
|
[7]
|
Ntzifa, A., Strati, A., Kallergi, G., Kotsakis, A., Georgoulias, V. and Lianidou, E. (2021) Gene Expression in Circulating Tumor Cells Reveals a Dynamic Role of EMT and PD-L1 dur-ing Osimertinib Treatment in NSCLC Patients. Scientific Reports, 11, Article No. 2313. https://doi.org/10.1038/s41598-021-82068-9
|
[8]
|
Peng, S., Wang, R., Zhang, X., et al. (2019) EGFR-TKI Re-sistance Promotes Immune Escape in Lung Cancer via Increased PD-L1 Expression. Molecular Cancer, 18, Article No. 165. https://doi.org/10.1186/s12943-019-1073-4
|
[9]
|
Chen, N., Fang, W., Zhan, J., et al. (2015) Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. Journal of Thoracic Oncology, 10, 910-923. https://doi.org/10.1097/JTO.0000000000000500
|
[10]
|
Osipov, A., Saung, M.T., Zheng, L. and Murphy, A.G. (2019) Small Molecule Immunomodulation: The Tumor Microenvironment and Overcoming Immune Escape. Journal for ImmunoTherapy of Cancer, 7, 224.
https://doi.org/10.1186/s40425-019-0667-0
|
[11]
|
Altorki, N.K., Markowitz, G.J., Gao, D., et al. (2019) The Lung Microenvironment: An Important Regulator of Tumour Growth and Metastasis. Nature Reviews Cancer, 19, 9-31. https://doi.org/10.1038/s41568-018-0081-9
|
[12]
|
郑玉军, 姜巍, 李晶, 代璐璐, 陈东妍, 李颜君, 黄磊, 王明吉. 免疫检查点抑制剂在EGFR突变型晚期非小细胞肺癌中的应用[J]. 中国肺癌杂志, 2022, 25(9): 671-677.
|
[13]
|
Yang, L., He, Y.T., Dong, S., et al. (2022) Single-Cell Transcriptome Analysis Revealed a Suppressive Tumor Immune Microenvironment in EGFR Mutant Lung Adenocarcinoma. Journal for ImmunoTherapy of Cancer, 10, e003534. https://doi.org/10.1136/jitc-2021-003534
|
[14]
|
Tuminello, S., Veluswamy, R., Lieberman-Cribbin, W., Gnjatic, S., Petralia, F., Wang, P., Flores, R. and Taioli, E. (2019) Prognostic Value of Immune Cells in the Tumor Mi-croenvironment of Early-Stage Lung Cancer: A Meta-Analysis. Oncotarget, 10, 7142-7155. https://doi.org/10.18632/oncotarget.27392
|
[15]
|
Sugiyama, E., Togashi, Y., Takeuchi, Y., et al. (2020) Blockade of EGFR Improves Responsiveness to PD-1 Blockade in EGFR-Mutated Non-Small Cell Lung Cancer. Science Immunol-ogy, 5, eaav3937.
https://doi.org/10.1126/sciimmunol.aav3937
|
[16]
|
Lin, A., Wei, T., Meng, H., Luo, P. and Zhang, J. (2019) Role of the Dynamic Tumor Microenvironment in Controversies Regarding Immune Checkpoint Inhibitors for the Treatment of Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations. Molecular Cancer, 18, Article No. 139. https://doi.org/10.1186/s12943-019-1062-7
|
[17]
|
Madeddu, C., Donisi, C., Liscia, N., Lai, E., Scartozzi, M. and Macciò, A. (2022) EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment. International Journal of Molecular Sciences, 23, Article 6489. https://doi.org/10.3390/ijms23126489
|
[18]
|
Matsumoto, Y., Sawa, K., Fukui, M., et al. (2019) Impact of Tumor Microenvironment on the Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. Cancer Science, 110, 3244-3254. https://doi.org/10.1111/cas.14156
|
[19]
|
Isomoto, K., Haratani, K., Hayashi, H., et al. (2020) Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer. Clinical Cancer Research, 26, 2037-2046.
https://doi.org/10.1158/1078-0432.CCR-19-2027
|
[20]
|
Jia, Y., Li, X., Jiang, T., et al. (2019) EGFR-Targeted Therapy Alters the Tumor Microenvironment in EGFR-Driven Lung Tumors: Implications for Combination Therapies. International Journal of Cancer, 145, 1432-1444.
https://doi.org/10.1002/ijc.32191
|
[21]
|
Liu, L., Wang, C., Li, S., Bai, H. and Wang, J. (2021) Tumor Immune Mi-croenvironment in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer before and after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment: A Narrative Review. Translational Lung Cancer Research, 10, 3823-3839.
https://doi.org/10.21037/tlcr-21-572
|
[22]
|
Liu, S., Wu, F., Li, X., et al. (2021) Patients with Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC. Frontiers in Oncology, 11, Article 639947. https://doi.org/10.3389/fonc.2021.639947
|
[23]
|
Akbay, E.A., Koyama, S., Carretero, J., et al. (2013) Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. Cancer Discovery, 3, 1355-1363. https://doi.org/10.1158/2159-8290.CD-13-0310
|
[24]
|
Azuma, K., Ota, K., Kawahara, A., et al. (2014) Association of PD-L1 Overexpression with Activating EGFR Mutations in Surgically Resected Nonsmall-Cell Lung Cancer. Annals of Oncology, 25, 1935-1940.
https://doi.org/10.1093/annonc/mdu242
|
[25]
|
石岩, 吕望, 汪路明, 等. 肺癌驱动基因与PD-1/PD-L1信号通路相互作用在非小细胞肺癌发生发展中的研究进展[J]. 中国肺癌杂志, 2017, 20(11): 781-786.
|
[26]
|
Lu, J., Li, J., Lin, Z., et al. (2023) Reprogramming of TAMs via the STAT3/CD47-SIRPα Axis Promotes Acquired Resistance to EGFR-TKIs in Lung Cancer. Cancer Letters, 564, Article ID: 216205.
https://doi.org/10.1016/j.canlet.2023.216205
|
[27]
|
Li, X., Lian, Z., Wang, S., Xing, L. and Yu, J. (2018) Interac-tions between EGFR and PD-1/PD-L1 Pathway: Implications for Treatment of NSCLC. Cancer Letters, 418, 1-9. https://doi.org/10.1016/j.canlet.2018.01.005
|
[28]
|
Lastwika, K.J., Wilson III., W., Li, Q.K., et al. (2016) Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Research, 76, 227-238.
https://doi.org/10.1158/0008-5472.CAN-14-3362
|
[29]
|
Abdelhamed, S., Ogura, K., Yokoyama, S., Saiki, I. and Hayakawa, Y. (2016) AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC Cells. Journal of Cancer, 7, 1579-1586.
https://doi.org/10.7150/jca.14713
|
[30]
|
Zhang, N., Zeng, Y., Du, W., et al. (2016) The EGFR Pathway Is Involved in the Regulation of PD-L1 Expression via the IL-6/JAK/STAT3 Signaling Pathway in EGFR-Mutated Non-Small Cell Lung Cancer. International Journal of Oncology, 49, 1360-1368. https://doi.org/10.3892/ijo.2016.3632
|
[31]
|
Concha-Benavente, F., Srivastava, R.M., Trivedi, S., et al. (2016) Iden-tification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Research, 76, 1031-1043. https://doi.org/10.1158/0008-5472.CAN-15-2001
|
[32]
|
Rangachari, D., VanderLaan, P.A., Shea, M., et al. (2017) Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥ 50% Expression in Lung Adenocarcinoma. Journal of Thoracic Oncology, 12, 878-883. https://doi.org/10.1016/j.jtho.2016.12.026
|
[33]
|
Gainor, J.F., Shaw, A.T., Sequist, L.V., et al. (2016) EGFR Muta-tions and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clinical Cancer Research, 22, 4585-4593. https://doi.org/10.1158/1078-0432.CCR-15-3101
|
[34]
|
Dong, Z.Y., Zhang, J.T., Liu, S.Y., et al. (2017) EGFR Mutation Correlates with Uninflamed Phenotype and Weak Immunogenicity, Causing Impaired Response to PD-1 Blockade in Non-Small Cell Lung Cancer. Oncoimmunology, 6, e1356145. https://doi.org/10.1080/2162402X.2017.1356145
|
[35]
|
D’Incecco, A., Andreozzi, M., Ludovini, V., et al. (2015) PD-1 and PD-L1 Expression in Molecularly Selected Non-Small-Cell Lung Cancer Patients. British Journal of Cancer, 112, 95-102. https://doi.org/10.1038/bjc.2014.555
|
[36]
|
Lin, C., Chen, X., Li, M., et al. (2015) Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients with Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. Clinical Lung Cancer, 16, E25-E35. https://doi.org/10.1016/j.cllc.2015.02.002
|
[37]
|
Kim, T., Cha, Y.J. and Chang, Y.S. (2020) Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Muta-tion-Positive Lung Adenocarcinoma. Tuberculosis and Respiratory Diseases, 83, 51-60. https://doi.org/10.4046/trd.2019.0026
|
[38]
|
Tang, Y., Fang, W., Zhang, Y., et al. (2015) The Association between PD-L1 and EGFR Status and the Prognostic Value of PD-L1 in Advanced Non-Small Cell Lung Cancer Patients Treated with EGFR-TKIs. Oncotarget, 6, 14209- 14219. https://doi.org/10.18632/oncotarget.3694
|
[39]
|
Chang, C.Y., Lai, Y.C., Wei, Y.F., Chen, C.Y. and Chang, S.C. (2021) PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment. OncoTargets and Therapy, 14, 2301-2309. https://doi.org/10.2147/OTT.S290445
|
[40]
|
Yoon, B.W., Chang, B. and Lee, S.H. (2020) High PD-L1 Expression Is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy. OncoTargets and Therapy, 13, 8273-8285. https://doi.org/10.2147/OTT.S271011
|
[41]
|
Hsu, P.C., Wang, C.W., Kuo, S.C., et al. (2020)The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma. Biomedicines, 8, Article 36.
https://doi.org/10.3390/biomedicines8020036
|
[42]
|
Yoneshima, Y., Ijichi, K., Anai, S., et al. (2018) PD-L1 Expres-sion in Lung Adenocarcinoma Harboring EGFR Mutations or ALK Rearrangements. Lung Cancer, 118, 36-40. https://doi.org/10.1016/j.lungcan.2018.01.024
|
[43]
|
Su, S., Dong, Z.Y., Xie, Z., et al. (2018) Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors among NSCLC Patients with EGFR Mutation. Journal of Thoracic Oncology, 13, 1668-1675. https://doi.org/10.1016/j.jtho.2018.07.016
|
[44]
|
Yang, C.Y., Liao, W.Y., Ho, C.C., et al. (2020) Association be-tween Programmed Death-Ligand 1 Expression, Immune Microenvironments, and Clinical Outcomes in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma patients Treated with Tyrosine Kinase Inhibitors. European Journal of Cancer, 124, 110-122.
https://doi.org/10.1016/j.ejca.2019.10.019
|